{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:11:24Z","timestamp":1783573884976,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41575-024-01015-x","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:02:47Z","timestamp":1731888167000},"page":"92-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unlocking CD8+ T cell potential in chronic hepatitis B virus infection"],"prefix":"10.1038","volume":"22","author":[{"given":"Valeria","family":"Fumagalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-2671","authenticated-orcid":false,"given":"Matteo","family":"Iannacone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","volume":"22","author":"M Iannacone","year":"2022","unstructured":"Iannacone, M. & Guidotti, L. G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 22, 19\u201332 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68\u201376 (2003).","journal-title":"J. Virol."},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","volume":"574","author":"AP B\u00e9n\u00e9chet","year":"2019","unstructured":"B\u00e9n\u00e9chet, A. P. et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574, 200\u2013205 (2019).","journal-title":"Nature"},{"key":"1015_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003490","volume":"9","author":"M Isogawa","year":"2013","unstructured":"Isogawa, M., Chung, J., Murata, Y., Kakimi, K. & Chisari, F. V. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog. 9, e1003490 (2013).","journal-title":"PLoS Pathog."},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Ann. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Ann. Rev. Immunol."},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1016\/j.cell.2024.05.038","volume":"187","author":"F Andreata","year":"2024","unstructured":"Andreata, F. et al. Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell 187, 4078\u20134094.e21 (2024).","journal-title":"Cell"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41590-024-01928-4","volume":"25","author":"K Heim","year":"2024","unstructured":"Heim, K. et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat. Immunol. 25, 1650\u20131662 (2024).","journal-title":"Nat. Immunol."},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","volume":"631","author":"M Bosch","year":"2024","unstructured":"Bosch, M. et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature 631, 867\u2013875 (2024).","journal-title":"Nature"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/hep.27254","volume":"60","author":"IN Crispe","year":"2014","unstructured":"Crispe, I. N. Immune tolerance in liver disease. Hepatology 60, 2109\u20132117 (2014).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01015-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T13:04:06Z","timestamp":1738242246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-01015-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-01015-x","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"18 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.I. participates in advisory boards, consults for or receives funding from Gilead Sciences, Asher Biotherapeutics, GentiBio, BlueJay Therapeutics, Aligos Therapeutics, HumAbs Biomed\/VIR Biotechnology, BioNTech, Excision BioTherapeutics\u00a0and Moderna. V.F. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}